Hansa Biopharma AB (publ) (HNSA.ST)
SEK 33.3
(17.42%)
SEK 33.3
(17.42%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 134.09 Million | 154.52 Million | 33.87 Million | 6.09 Million | 3.36 Million | 3.35 Million |
| Cost of Revenue | 63.14 Million | 38.47 Million | 15.42 Million | 997 Thousand | 866 Thousand | 916 Thousand |
| Gross Profit | 70.95 Million | 116.04 Million | 18.45 Million | 5.1 Million | 2.49 Million | 2.44 Million |
| Operating Expenses | 859.44 Million | 692.16 Million | 558.03 Million | 430.17 Million | 360.09 Million | 244.22 Million |
| Selling, General and Administrative Expenses | 450.49 Million | 337.86 Million | 327.26 Million | 202.98 Million | 167.31 Million | 90.38 Million |
| Research and Development Expenses | 411.33 Million | 346.24 Million | 230.76 Million | 227.19 Million | 192.94 Million | 154.55 Million |
| Other Expenses | -2.37 Million | 8.06 Million | - | - | -166 Thousand | -725 Thousand |
| Cost and Expenses | 922.59 Million | 730.64 Million | 573.45 Million | 431.17 Million | 360.95 Million | 245.13 Million |
| Operating Income | -788.49 Million | -576.12 Million | -539.58 Million | -425.07 Million | -357.59 Million | -246.49 Million |
| Interest Expense | 105.52 Million | 43.66 Million | 694 Thousand | 257 Thousand | 466 Thousand | 706 Thousand |
| Income Tax Expense | 908 Thousand | 1.15 Million | 152 Thousand | -40 Thousand | 417 Thousand | -40 Thousand |
| Earnings before Tax | -830.81 Million | -609.97 Million | -548.13 Million | -420.89 Million | -359.59 Million | -248.01 Million |
| Net Income | -831.72 Million | -611.13 Million | -548.28 Million | -420.85 Million | -360 Million | -247.97 Million |
| Earnings Per Share Basic | -15.83 | -13.60 | -12.33 | -9.98 | -9.00 | -6.47 |
| Earnings Per Share Diluted | -15.83 | -13.60 | -12.33 | -9.98 | -9.00 | -6.47 |
| Weighted Average Shares Outstanding | 52.54 Million | 44.92 Million | 44.47 Million | 42.17 Million | 40.02 Million | 38.32 Million |
| Weighted Average Shares Outstanding (Diluted) | 52.54 Million | 44.92 Million | 44.47 Million | 42.17 Million | 40.02 Million | 38.32 Million |
| Gross Margin | 0.53 | 0.75 | 0.54 | 0.84 | 0.74 | 0.73 |
| EBIT Margin | -5.33 | -3.55 | -15.89 | -68.01 | -104.67 | -72.85 |
| Profit Margin | -6.20 | -3.95 | -16.18 | -69.01 | -107.02 | -73.85 |
| EBITDA | -714.55 Million | -554.25 Million | -538.83 Million | -413.08 Million | -352.21 Million | -245.47 Million |
| Earnings Before Tax Margin | -5.88 | -3.73 | -15.93 | -69.71 | -106.30 | -73.41 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 48.66 Million | 34.33 Million | 55.98 Million | 134.09 Million | 50.41 Million | 22.83 Million |
| Cost of Revenue | 11.38 Million | 40.52 Million | 18.15 Million | 64.82 Million | 18.12 Million | 16.65 Million |
| Gross Profit | 37.28 Million | -6.19 Million | 37.82 Million | 69.26 Million | 32.28 Million | 6.18 Million |
| Operating Expenses | 154.21 Million | 175.48 Million | 190.71 Million | 860.13 Million | 214.24 Million | 208.33 Million |
| Selling, General and Administrative Expenses | 75.81 Million | 88.2 Million | 87.75 Million | - | 105.99 Million | 111.73 Million |
| Research and Development Expenses | 79.62 Million | 87.27 Million | 102.96 Million | - | 108.25 Million | 95.55 Million |
| Other Expenses | -1.23 Million | 1.3 Million | - | - | - | - |
| Cost and Expenses | 165.59 Million | 216.01 Million | 208.87 Million | 924.96 Million | 232.36 Million | 224.99 Million |
| Operating Income | -116.92 Million | -181.67 Million | -152.89 Million | -790.87 Million | -181.95 Million | -202.15 Million |
| Interest Expense | - | 26.51 Million | 64.36 Million | 105.52 Million | - | 48.28 Million |
| Income Tax Expense | 126 Thousand | -14 Thousand | 61 Thousand | 908 Thousand | 214 Thousand | 219 Thousand |
| Earnings before Tax | -103.67 Million | -207.92 Million | -218.51 Million | -830.81 Million | -124.24 Million | -250.43 Million |
| Net Income | -103.79 Million | -207.94 Million | -218.57 Million | -831.72 Million | -124.45 Million | -250.65 Million |
| Earnings Per Share Basic | -1.53 | -3.30 | -4.15 | - | -2.36 | -4.78 |
| Earnings Per Share Diluted | -1.53 | -3.30 | -4.15 | - | -2.36 | -4.78 |
| Weighted Average Shares Outstanding | 67.81 Million | 62.92 Million | 52.67 Million | 52.54 Million | 52.67 Million | 52.44 Million |
| Weighted Average Shares Outstanding (Diluted) | 67.81 Million | 62.92 Million | 52.67 Million | 52.54 Million | 52.67 Million | 52.44 Million |
| Gross Margin | 0.77 | -0.18 | 0.68 | 0.52 | 0.64 | 0.27 |
| EBIT Margin | -2.40 | -5.28 | -2.75 | - | -2.23 | -8.85 |
| Profit Margin | -2.13 | -6.06 | -3.90 | -6.20 | -2.47 | -10.98 |
| EBITDA | -116.92 Million | -181.41 Million | -154.15 Million | - | -112.33 Million | -202.15 Million |
| Earnings Before Tax Margin | -2.40 | -5.29 | -2.73 | -5.90 | -3.61 | -8.85 |
CFF
688659
IR5B
1951
GCAN
CWXZF